Skip to main content
. 2023 Apr 20;24(8):7581. doi: 10.3390/ijms24087581

Table 1.

Clinical trials of Tezepelumab administration in asthma patients.

Study Title Study Identifier Study Phase Outcome Refs.
Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma NCT01405963 Ib

  • Attenuation of FEV1 decline

  • Inhibition of methacholine-induced airway hyperresponsivenes

 [165]
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) NCT03688074 II Reduction of:

  • airway submucosal eosinophils in bronchial biopsies

  • peripheral blood eosinophils

  • AHR

  • disease exacerbation

 [166]
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (PATHWAY) NCT02054130 IIb

  • Reduction of asthma exacerbations

  • Improvement of lung function

  • Improvement of asthma control and health-related quality of life of patients

 [167,168]
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR) NCT03347279 III

  • Reduction of asthma exacerbations

  • Amelioration of lung function

  • Reduction of hospitalization and emergency room visits

 [169]
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) NCT03706079 III

  • Reduction of the annualised asthma exacerbation rate

 [170]